CASI Pharmaceuticals Advances Anti-CD38 Antibody CID-103 To Next Dose Cohort In Phase 1 ITP Trial

- CID-103 is a potential best-in-class, clinical stage anti-CD38 monoclonal antibody

- Safety profile observed in first four dose cohorts supports continued development

- No serious adverse events or dose-limiting toxicities have been reported

SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / September 8, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today announced that the Safety Monitoring Committee (SMC) has completed its review of cohort 4 (600 mg target dose) along with its continued assessment of the first three cohorts of the company's Phase 1 dose-escalating and safety study of CID-103 in adults with chronic immune thrombocytopenia (ITP). The SMC has recommended that the trial continue and the dose escalation to cohort 5 (900 mg target dose) may proceed as per the protocol design.